Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin‐Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Issue 4 (29th March 2020)

• Record Type: Journal Article
• Authors: Rybak, Michael J.; Le, Jennifer; Lodise, Thomas P.; Levine, Donald P.; Bradley, John S.; Liu, Catherine; Mueller, Bruce A.; Pai, Manjunath P.; Wong‐Beringer, Annie; Rotschafer, John C.; Rodvold, Keith A.; Maples, Holly D.; Lomaestro, Benjamin M.
• Is Part Of: Pharmacotherapy. Volume 40:Issue 4(2020)
• Page Start: 363
• Page End: 367
• Publication Date: 2020-03-29
• Subjects: vancomycin consensus guidelines -- vancomycin -- pharmacokinetics and pharmacodynamics -- target attainment -- nephrotoxicity; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2376
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract : Background: Recent vancomycin PK/PD and toxicodynamic studies enable a reassessment of the current dosing and monitoring guideline in an attempt to further optimize the efficacy and safety of vancomycin therapy. The area‐under‐the‐curve to minimum inhibitory concentration (AUC/MIC) has been identified as the most appropriate pharmacokinetic/pharmacodynamic (PK/PD) target for vancomycin. The 2009 vancomycin consenus guidelines recommended specific trough concentrations as a surrogate marker for AUC/MIC. However, more recent toxicodynamic studies have reported an increase in nephrotoxicity associated with trough monitoring. Methods and Results: This is the executive summary of the new vancomycin consensus guidelines for dosing and monitoring vancomycin therapy and was developed by the American Society of Health‐Systems Pharmacists, Infectious Diseases Society of America, Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists vancomycin consensus guidelines committee. Conclusions: The recommendations provided in this document are intended to assist the clinician in optimizing vancomycin for the treatment of invasive MRSA infections in adult and pediatric patients. An AUC/MIC by broth microdilution (BMD) ratio of 400 to 600 (assuming MICBMD of 1 mg/L) should be advocated as the target to achieve clinical efficacy while improving patient safety for patients with serious MRSA infections. In such cases, AUC‐guided dosing and monitoring is the most accurate and optimal way to manage vancomycin therapy.